세계의 바이러스 벡터 및 플라스미드 DNA 제조 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)

The global market for Viral Vectors and Plasmid DNA Manufacturing was estimated to be worth US$ 668 million in 2024 and is forecast to a readjusted size of US$ 4511 million by 2031 with a CAGR of 31.8% during the forecast period 2025-2031.

Viral vectors and plasmid DNA manufacturing represent essential infrastructure in the gene and cell therapy value chain, enabling the delivery and expression of therapeutic genes. Viral vectors-including AAV, adenovirus, and lentivirus-are foundational to CAR-T therapies, gene editing platforms, and vaccine development due to their efficient gene transfer capabilities. Plasmid DNA, as a crucial upstream component, supports viral vector production, mRNA synthesis, and DNA vaccine development. As gene and cell therapies move toward large-scale commercialization, GMP-grade manufacturing capacity of viral vectors and plasmid DNA has become a strategic focal point for biopharma companies, CDMO platforms, and global investors.

As gene and cell therapies gain global regulatory approvals, demand for industrial-scale manufacturing of viral vectors and plasmid DNA is rapidly expanding. Blockbuster CAR-T products, AAV gene therapies, and mRNA vaccines continue to scale up, fueling the need for GMP-compliant platforms, robust quality systems, and high-purity raw materials. CDMO players are becoming the core force in industrial upgrading under the "asset-light" strategies of pharmaceutical companies. Governments worldwide are also promoting bio-manufacturing capacity through strategic funding, infrastructure support, and policy initiatives aimed at localization, modularity, and automation. The industry faces significant technical and operational barriers, including high production costs, lack of standardized processes, and stringent quality control challenges. Key bottlenecks persist in high-purity plasmid preparation and efficient viral vector production, particularly in impurity removal and yield optimization. Regulatory frameworks are evolving rapidly across different regions, requiring manufacturers to navigate diverse GMP compliance requirements and stricter approval thresholds. Additionally, the high concentration of capacity among top-tier CDMOs intensifies competition and pricing pressure, raising the market entry threshold for emerging players. The downstream market is transitioning from academic labs and early-stage biotech firms to commercial-stage biopharmaceutical companies, with order volumes scaling from grams to kilograms. AAV, LNP-mRNA, and CAR-T pipelines heavily rely on customized viral vectors and high-quality plasmids. In rare diseases, oncology, and vaccine development, demand is rising for delivery tools with enhanced expression, reduced immunogenicity, and controlled safety. This is driving the construction of scalable, modular GMP manufacturing systems that can meet precise, application-specific requirements.

This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Viral Vectors and Plasmid DNA Manufacturing by region & country, by Type, and by Application.

The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.

Market Segmentation

By Company

• Thermo Fisher Scientific
• Lonza
• Azenta Life Sciences
• Revvity
• VectorBuilder
• Takara Bio
• GenScript Biotech
• Gene Chem
• Geno Meditech
• PackGene Biotech
• VIROVEK
• OriGen
• Vector BioLabs

Segment by Type

• AAV
• Lentiviruses
• Retroviruses
• Adenoviruses
• DNA Plasmids
• Other

Segment by Application

• Pharmaceutical and Biopharmaceutical Companies
• Academics and Research Institutes

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Viral Vectors and Plasmid DNA Manufacturing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Viral Vectors and Plasmid DNA Manufacturing in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Viral Vectors and Plasmid DNA Manufacturing Product Introduction
• 1.2 Global Viral Vectors and Plasmid DNA Manufacturing Market Size Forecast (2020-2031)
• 1.3 Viral Vectors and Plasmid DNA Manufacturing Market Trends & Drivers
  • 1.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends
  • 1.3.2 Viral Vectors and Plasmid DNA Manufacturing Market Drivers & Opportunity
  • 1.3.3 Viral Vectors and Plasmid DNA Manufacturing Market Challenges
  • 1.3.4 Viral Vectors and Plasmid DNA Manufacturing Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Viral Vectors and Plasmid DNA Manufacturing Players Revenue Ranking (2024)
• 2.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue by Company (2020-2025)
• 2.3 Key Companies Viral Vectors and Plasmid DNA Manufacturing Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Viral Vectors and Plasmid DNA Manufacturing Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Viral Vectors and Plasmid DNA Manufacturing
• 2.6 Viral Vectors and Plasmid DNA Manufacturing Market Competitive Analysis
  • 2.6.1 Viral Vectors and Plasmid DNA Manufacturing Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Viral Vectors and Plasmid DNA Manufacturing Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors and Plasmid DNA Manufacturing as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 AAV
  • 3.1.2 Lentiviruses
  • 3.1.3 Retroviruses
  • 3.1.4 Adenoviruses
  • 3.1.5 DNA Plasmids
  • 3.1.6 Other
• 3.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type
  • 3.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Type (2020-2031)
  • 3.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Pharmaceutical and Biopharmaceutical Companies
  • 4.1.2 Academics and Research Institutes
• 4.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application
  • 4.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Application (2020-2031)
  • 4.2.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region
  • 5.1.1 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2020-2025)
  • 5.1.3 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (2026-2031)
  • 5.1.4 Global Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 5.2.2 North America Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 5.3.2 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 5.5.2 South America Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 6.3.2 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 6.4.2 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 6.5.2 China Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 6.6.2 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 6.7.2 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Viral Vectors and Plasmid DNA Manufacturing Sales Value, 2020-2031
  • 6.9.2 India Viral Vectors and Plasmid DNA Manufacturing Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Viral Vectors and Plasmid DNA Manufacturing Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Thermo Fisher Scientific
  • 7.1.1 Thermo Fisher Scientific Profile
  • 7.1.2 Thermo Fisher Scientific Main Business
  • 7.1.3 Thermo Fisher Scientific Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.1.4 Thermo Fisher Scientific Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Thermo Fisher Scientific Recent Developments
• 7.2 Lonza
  • 7.2.1 Lonza Profile
  • 7.2.2 Lonza Main Business
  • 7.2.3 Lonza Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.2.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.2.5 Lonza Recent Developments
• 7.3 Azenta Life Sciences
  • 7.3.1 Azenta Life Sciences Profile
  • 7.3.2 Azenta Life Sciences Main Business
  • 7.3.3 Azenta Life Sciences Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.3.4 Azenta Life Sciences Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.3.5 Azenta Life Sciences Recent Developments
• 7.4 Revvity
  • 7.4.1 Revvity Profile
  • 7.4.2 Revvity Main Business
  • 7.4.3 Revvity Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.4.4 Revvity Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.4.5 Revvity Recent Developments
• 7.5 VectorBuilder
  • 7.5.1 VectorBuilder Profile
  • 7.5.2 VectorBuilder Main Business
  • 7.5.3 VectorBuilder Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.5.4 VectorBuilder Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.5.5 VectorBuilder Recent Developments
• 7.6 Takara Bio
  • 7.6.1 Takara Bio Profile
  • 7.6.2 Takara Bio Main Business
  • 7.6.3 Takara Bio Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.6.4 Takara Bio Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Takara Bio Recent Developments
• 7.7 GenScript Biotech
  • 7.7.1 GenScript Biotech Profile
  • 7.7.2 GenScript Biotech Main Business
  • 7.7.3 GenScript Biotech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.7.4 GenScript Biotech Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.7.5 GenScript Biotech Recent Developments
• 7.8 Gene Chem
  • 7.8.1 Gene Chem Profile
  • 7.8.2 Gene Chem Main Business
  • 7.8.3 Gene Chem Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.8.4 Gene Chem Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.8.5 Gene Chem Recent Developments
• 7.9 Geno Meditech
  • 7.9.1 Geno Meditech Profile
  • 7.9.2 Geno Meditech Main Business
  • 7.9.3 Geno Meditech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.9.4 Geno Meditech Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Geno Meditech Recent Developments
• 7.10 PackGene Biotech
  • 7.10.1 PackGene Biotech Profile
  • 7.10.2 PackGene Biotech Main Business
  • 7.10.3 PackGene Biotech Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.10.4 PackGene Biotech Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.10.5 PackGene Biotech Recent Developments
• 7.11 VIROVEK
  • 7.11.1 VIROVEK Profile
  • 7.11.2 VIROVEK Main Business
  • 7.11.3 VIROVEK Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.11.4 VIROVEK Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.11.5 VIROVEK Recent Developments
• 7.12 OriGen
  • 7.12.1 OriGen Profile
  • 7.12.2 OriGen Main Business
  • 7.12.3 OriGen Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.12.4 OriGen Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.12.5 OriGen Recent Developments
• 7.13 Vector BioLabs
  • 7.13.1 Vector BioLabs Profile
  • 7.13.2 Vector BioLabs Main Business
  • 7.13.3 Vector BioLabs Viral Vectors and Plasmid DNA Manufacturing Products, Services and Solutions
  • 7.13.4 Vector BioLabs Viral Vectors and Plasmid DNA Manufacturing Revenue (US$ Million) & (2020-2025)
  • 7.13.5 Vector BioLabs Recent Developments

8 Industry Chain Analysis

• 8.1 Viral Vectors and Plasmid DNA Manufacturing Industrial Chain
• 8.2 Viral Vectors and Plasmid DNA Manufacturing Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Viral Vectors and Plasmid DNA Manufacturing Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Viral Vectors and Plasmid DNA Manufacturing Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer